{"id":1010476,"date":"2026-10-15T07:17:13","date_gmt":"2026-10-15T11:17:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectar-biosciences-presents-compelling-efficacy-data-from-phase-2b-clover-wam-subset-analysis-of-iopofosine-i-131-in-patients-relapsed-refractory-to-btk-inhibitor-therapy-at-the-international-works\/"},"modified":"2026-10-15T07:17:13","modified_gmt":"2026-10-15T11:17:13","slug":"cellectar-biosciences-presents-compelling-efficacy-data-from-phase-2b-clover-wam-subset-analysis-of-iopofosine-i-131-in-patients-relapsed-refractory-to-btk-inhibitor-therapy-at-the-international-works","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectar-biosciences-presents-compelling-efficacy-data-from-phase-2b-clover-wam-subset-analysis-of-iopofosine-i-131-in-patients-relapsed-refractory-to-btk-inhibitor-therapy-at-the-international-works\/","title":{"rendered":"Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed\/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenstr\u00f6m Macroglobulinemia"},"content":{"rendered":"
\n

\n Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months\u00a0<\/em>\n <\/p>\n

\n Initiation and site selections for Phase 3 confirmatory randomized clinical trial in post-first line, post-BTKi population evaluating Progression-Free Survival as primary endpoint underway; dosing of first patients expected in 1Q27 and application for U.S. accelerated market approval anticipated in 1H27<\/em>\n <\/p>\n

FLORHAM PARK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the company\u2019s Phase 2b CLOVER WaM clinical trial of iopofosine I 131 to treat relapsed or refractory (r\/r) Waldenstr\u00f6m macroglobulinemia (WM) were presented today at the International Workshop for Waldenstr\u00f6m Macroglobulinemia (IWWM) taking place October 14 to October 16, 2026, in Palm Springs, California.<\/p>\n

The poster highlighted data from a subgroup (n=24) of patients treated with a BTKi immediately prior to iopofosine I 131 from the CLOVER WaM trial in WM. This subgroup analysis is derived from the CLOVER WaM clinical trial 12-month follow-up data set<\/a> previously reported.<\/p>\n

\u201cThese compelling data further strengthen the growing body of evidence supporting the potential of iopofosine I 131 to address a critical unmet need and offers something WM patients rarely get after BTK inhibitors: deep, durable responses from a short, fixed course of treatment. Because its targeted radiation works independently of the BTK pathway and other pathways currently targeted or attempting to be targeted, we believe it has the potential to remain effective as patients become refractory to today\u2019s targeted therapies, and those still to come,\u201d said Jarrod Longcor, chief operating officer of Cellectar Biosciences. \u201cPatients in the immediate post-BTKi setting often face limited treatment options and increasingly refractory disease, making the robust response rates, durable clinical benefit, and favorable tolerability profile observed in this analysis especially encouraging. With Breakthrough Therapy Designation, a mature and expanding CLOVER WaM dataset, and plans underway to dose patients in our confirmatory clinical trial in early 2027, we believe iopofosine I 131 is well positioned to become a meaningful new treatment option for these patients, and we remain focused on advancing the program toward potential regulatory approval.\u201d<\/p>\n

\n Summary of Results in Subgroup Immediately post-BTKi treatment (n=24)<\/strong>
\n
The patients included in this subset analysis were enrolled in the CLOVER WaM clinical trial and were treated with iopofosine I 131 immediately after receiving a regimen containing BTKi. Seventy-five percent were BTKi refractory and more than 54% had received multiple BTKi therapies. Patients had a median of three prior lines of therapy (range 2-7) with 17% being TP53 mutated and 29% being MYD88 wild type, both of which confer greater resistance and rapid progression. Key findings included:<\/p>\n